Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma
Irene M. Ghobrial, Chia Jen Liu, Oksana Zavidij, Abdel K. Azab, Rachid Baz, Jacob P. Laubach, Yuji Mishima, Philippe Armand, Nikhil C. Munshi, Frank Basile, Michael Constantine, James Vredenburgh, Adam Boruchov, Pamela Crilley, Patrick M. Henrick, Kalvis T.V. Hornburg, Houry Leblebjian, Stacey Chuma, Kaitlen Reyes, Kimberly NoonanDiane Warren, Robert Schlossman, Claudia Paba-Prada, Kenneth C. Anderson, Edie Weller, Lorenzo Trippa, Kenneth Shain, Paul G. Richardson
Dive into the research topics of 'Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.